Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States.
暂无分享,去创建一个
[1] J. Lang. Survival for Patients With Invasive Cutaneous Melanoma Among Ethnic Groups: The Effects of Socioeconomic Status and Treatment , 2009 .
[2] Amy Y. Chen,et al. Association of Insurance Status and Ethnicity With Cancer Stage at Diagnosis for 12 Cancer Sites: A Retrospective Analysis , 2008 .
[3] Amy Y. Chen,et al. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). , 2008, Journal of the National Cancer Institute.
[4] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[5] J. Thomas,et al. Prognostic false-positivity of the sentinel node in melanoma , 2008, Nature Clinical Practice Oncology.
[6] S. Rosenberg. Why perform sentinel-lymph-node biopsy in patients with melanoma? , 2008, Nature Clinical Practice Oncology.
[7] C. Ko,et al. The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States , 2008, Annals of Surgical Oncology.
[8] D. Coit,et al. Multivariate prognostic model for patients with thick cutaneous melanoma: Importance of sentinel lymph node status , 2002, Annals of Surgical Oncology.
[9] J. Lang. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study , 2007 .
[10] P. G. Lang,et al. Sentinel-Node Biopsy or Nodal Observation in Melanoma , 2007 .
[11] E. Gershenwald. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy , 2007, Annals of Surgical Oncology.
[12] C. Balch,et al. Sentinel-node biopsy in melanoma. , 2006, The New England journal of medicine.
[13] N. Cascinelli,et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Balch,et al. Socioeconomic and demographic factors associated with use of sentinel node biopsy and adjuvant biologic response modifiers in melanoma. , 2006, Journal of Clinical Oncology.
[15] C. Masi,et al. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Charles R. Thomas,et al. Disparities in cancer care: a worldwide perspective and roadmap for change. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] O. Olopade,et al. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Xianglin L. Du,et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Soong,et al. Clinical Significance of Occult Metastatic Melanoma in Sentinel Lymph Nodes and Other High-risk Factors Based on Long-term Follow-up , 2005, World Journal of Surgery.
[20] K. McMasters. What Good is Sentinel Lymph Node Biopsy for Melanoma if it does not Improve Survival? , 2004, Annals of surgical oncology.
[21] Jeremy MG Taylor,et al. Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model , 2004, Annals of Surgical Oncology.
[22] A. Stewart,et al. The National Cancer Data Base: A clinical surveillance and quality improvement tool , 2004 .
[23] C. Begg,et al. The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes , 2003, Annals of Internal Medicine.
[24] E. McGlynn,et al. The quality of health care delivered to adults in the United States. , 2003, The New England journal of medicine.
[25] Jeffrey E. Lee,et al. Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients , 2003, Annals of Surgical Oncology.
[26] H. Gietema,et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Ross,et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. , 2002, American journal of surgery.
[28] S. Dinehart,et al. Sentinel node biopsy for melanoma: what is the evidence? , 2001, Archives of dermatology.
[29] M. Ross,et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Ross,et al. Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy , 2001, Annals of Surgical Oncology.
[31] M. Ross,et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] B. Eisenberg,et al. NCCN MELANOMA PRACTICE GUIDELINES , 1998 .
[33] A. Buzaid,et al. NCCN melanoma practice guidelines. National Comprehensive Cancer Network. , 1998, Oncology.
[34] R. Lew,et al. Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts. , 1996, American journal of public health.
[35] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[36] D L Morton,et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.
[37] R. Deyo,et al. ADAPTING A CLINICAL COMORBIDITY USE WITH ICD-g-CM ADMINISTRATIVE INDEX FOR DATABASES , 1992 .
[38] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[39] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.